$SUNPHARMA Sun Pharma announced the acquisition

Key Highlights Strategic Acquisition Sun Pharma announced the acquisition of Innovcare Lifesciences for ₹271 crore in an all‑cash deal. The move strengthens its nutraceutical and cosmeceutical product range under the consumer‑health division. Integration expected to complete by July 2026. Global Specialty Focus Continued strong performance in Ilumya, Winlevi, and Cequa across the US and EU markets. Specialty segment now contributes ~38% of global revenue, up from 33% last year. R&D and Pipeline R&D spend: ₹1,013 crore (6.9% of sales). Advancing biosimilar and oncology drug pipeline for FY27 launches. Focus on AI‑driven drug discovery and digital clinical trial management. Financial Performance (Q4 FY26) Revenue: ₹14,559.8 Cr (+13.6% YoY) Net Profit: ₹2,714 Cr (+26.2% YoY) EBITDA Margin: 25.9% (vs 25.2% YoY) Dividend: ₹5/share final; total FY26 dividend ₹16/share.